Nu.Q H3.1
Determine levels of H3.1-containing, circulating cell-free nucleosomes
Nucleosomes: The Next Generation of Cancer Biomarkers
A nucleosome, composed of histone proteins and the DNA wrapped around them, is the core unit of chromatin. The affect nucleosomes have on chromatin structure and gene regulation is dependent upon the identity of the histones that make up the nucleosome, as well as any modifications to these histone proteins. With a plethora of histone protein variants and post-translational modifications that can occur on their “histone tails”, there are a vast number of possibilities when it comes to the exact identiity of a nucleosome and its function. Recently, some of these variants and modifications have been found to associate with cancers. Furthermore, just the total amount of nucleosomes detected can also indicate a disease state or correlate with efficacy of therapy.
Recently, “liquid biopsies”, or blood draws from which you can examine biomarkers, have taken hold as an easy, less invasive method to monitor disease state and treatment efficacy. Nucleosomes, histones, and DNA can be shed into the blood during cancer due to high cellular turnover or in response to chemotherapy. Free-floating DNA (cfDNA and ctDNA) is an attractive biomarker, but has shown to be less stable than nucleosomes. Additionally, next generation sequencing of DNA is cumbersome and costly compared to a high-throughput ELISA assay to detect intact nucleosomes. Nucleosome-specific detection assays represent a new generation of biomarker tests: easy, fast, cost-effective, and compatible with stable proteins in liquid biopsy samples.
Histone H3.1
Active Motif’s Nu.Q H3.1 Assay Kit is designed for the detection of levels of Histone H3.1-containing, circulating cell-free nucleosomes (cf-nucleosomes) in human serum in a high-throughput format. Histone H3.1, or the canonical form of Histone H3, is deposited during DNA replication and possibly also during repair. Study of H3.1 has identified cancer-associated mutations and differing affinities for the histone acetyltransferase HAT1. To examine H3-containing nucleosome for all variants, use our Nu.Q H3 Assay. For added convenience and a more quantitative interpretation of results, the Nu.Q H3.1 Assay Kit also includes a recombinant nucleosome protein for use as a reference standard curve. For complete details, click the Nu.Q Method tab below.
Why use Nu.Q H3.1?
- Sensitivity: Detect circulating nucleosomes in as little as 10 µl of serum or 20 µl of plasma
- Specificity: Nucleosome epitope specific antibody enables detection of only intact nucleosomes
- Quantification: Recombinant nucleosomes enable relative quantification of levels of circulating H3.1 nucleosomes
- Convenience: Colorimetric assay in a simple 96-stripwell format for high and low throughput
- Fast: Results can be obtained in 5 hoursA nucleosome, composed of histone proteins and the DNA wrapped around them, is the core unit of chromatin. The affect nucleosomes have on chromatin structure and gene regulation is dependent upon the identity of the histones that make up the nucleosome, as well as any modifications to these histone proteins. With a plethora of histone protein variants and post-translational modifications that can occur on their “histone tails”, there are a vast number of possibilities when it comes to the exact identiity of a nucleosome and its function. Recently, some of these variants and modifications have been found to associate with cancers. Furthermore, just the total amount of nucleosomes detected can also indicate a disease state or correlate with efficacy of therapy.
Recently, “liquid biopsies”, or blood draws from which you can examine biomarkers, have taken hold as an easy, less invasive method to monitor disease state and treatment efficacy. Nucleosomes, histones, and DNA can be shed into the blood during cancer due to high cellular turnover or in response to chemotherapy. Free-floating DNA (cfDNA and ctDNA) is an attractive biomarker, but has shown to be less stable than nucleosomes. Additionally, next generation sequencing of DNA is cumbersome and costly compared to a high-throughput ELISA assay to detect intact nucleosomes. Nucleosome-specific detection assays represent a new generation of biomarker tests: easy, fast, cost-effective, and compatible with stable proteins in liquid biopsy samples.
) Cortisol in Saliva Elisa Kit (RUO) |
|||
| 55R-RE52061 | Fitzgerald | 96 wells | EUR 358 |
|
Description: ELISA kit for detection of Free Cortisol in Saliva in the research laboratory |
|||
 Tertiapin-Q |
|||
| B5090-1 | ApexBio | 1 mg | EUR 547 |
 NU 1025 |
|||
| 2351-5 | Biovision | EUR 262 | |
 NU-7026 |
|||
| B2522-25 | Biovision | EUR 544 | |
NU-7026 |
|||
| B2522-5 | Biovision | EUR 175 | |
 NU-7441 |
|||
| B1117-25 | Biovision | EUR 544 | |
NU-7441 |
|||
| B1117-5 | Biovision | EUR 175 | |
 NU 7026 |
|||
| A8649-10 | ApexBio | 10 mg | EUR 137 |
|
Description: NU 7026 is a selective inhibitor of DNA-PK with IC50 value of 0.23 ?M [1]. |
|||
NU 7026 |
|||
| A8649-50 | ApexBio | 50 mg | EUR 421 |
|
Description: NU 7026 is a selective inhibitor of DNA-PK with IC50 value of 0.23 ?M [1]. |
|||
 Nu 6027 |
|||
| A1986-10 | ApexBio | 10 mg | EUR 176 |
|
Description: NU6027 is a potent inhibitor of cellular ATR activity with the IC50 of 6.7 ?M.The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a crucial role in the stalled replication forks signalling and DNA damage to cell cycle checkpoints and DNA repair. |
|||
Nu 6027 |
|||
| A1986-5 | ApexBio | 5 mg | EUR 129 |
|
Description: NU6027 is a potent inhibitor of cellular ATR activity with the IC50 of 6.7 ?M.The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a crucial role in the stalled replication forks signalling and DNA damage to cell cycle checkpoints and DNA repair. |
|||
Nu 6027 |
|||
| A1986-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 131 |
|
Description: NU6027 is a potent inhibitor of cellular ATR activity with the IC50 of 6.7 ?M.The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a crucial role in the stalled replication forks signalling and DNA damage to cell cycle checkpoints and DNA repair. |
|||
Nu 6027 |
|||
| A1986-50 | ApexBio | 50 mg | EUR 547 |
|
Description: NU6027 is a potent inhibitor of cellular ATR activity with the IC50 of 6.7 ?M.The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a crucial role in the stalled replication forks signalling and DNA damage to cell cycle checkpoints and DNA repair. |
|||
 NU 9056 |
|||
| A4492-10 | ApexBio | 10 mg | EUR 284 |
|
Description: Selective KAT5 (Tip60) histone acetyltransferase inhibitor (IC50 values are 100 ?M for KAT5, p300, pCAF and GCN5, respectively). Inhibits protein acetylation in prostate cancer cell lines and blocks DNA damage response. |
|||
NU 1025 |
|||
| A4530-25 | ApexBio | 25 mg | EUR 440 |
|
Description: Novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively. |
|||
NU 1025 |
|||
| A4530-5 | ApexBio | 5 mg | EUR 180 |
|
Description: Novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively. |
|||
NU 1025 |
|||
| A4530-50 | ApexBio | 50 mg | EUR 788 |
|
Description: Novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively. |
|||
NU 7026 |
|||
| HY-15719 | MedChemExpress | 10mM/1mL | EUR 126 |
 Q-VD-OPh |
|||
| 1170-1 | Biovision | EUR 234 | |
) anti-PKC nu (Protein kinase C nu) |
|||
| LF-PA0073 | Abfrontier | 100 ul | EUR 334 |
|
Description: Rabbit polyclonal to PKC nu (Protein kinase C nu) |
|||
 Antibody) Protein Kinase C Nu Type (PKC nu) Antibody |
|||
| abx033122-400ul | Abbexa | 400 ul | EUR 523 |
Protein Kinase C Nu Type (PKC nu) Antibody |
|||
| abx033122-80l | Abbexa | 80 µl | EUR 286 |
Protein Kinase C Nu Type (PKC nu) Antibody |
|||
| abx033123-400ul | Abbexa | 400 ul | EUR 523 |
Protein Kinase C Nu Type (PKC nu) Antibody |
|||
| abx033123-80l | Abbexa | 80 µl | EUR 286 |
 EZSolution? Q-VD-OPh |
|||
| 1173-1 | Biovision | EUR 207 | |
 EZSolution? Q-DEVD-OPh |
|||
| 1178-1 | Biovision | EUR 272 | |
-OPh) Q-VD(OMe)-OPh |
|||
| A8165-1 | ApexBio | 1 mg | EUR 177 |
|
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor, provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors. |
|||
 Q-VD-OPh hydrate |
|||
| A1901-1 | ApexBio | 1 mg | EUR 177 |
|
Description: The broad spectrum caspase inhibitor, QVD-OPh, provides a cost effective, non toxic, and highly speci?c means of apoptotic inhibition and provides new insight into the design of new inhibitors1. |
|||
 PKC nu protein |
|||
| 30R-2860 | Fitzgerald | 5 ug | EUR 503 |
|
Description: Purified recombinant Human PKC nu protein |
|||
 PKC nu antibody |
|||
| 20R-2919 | Fitzgerald | 100 ul | EUR 393 |
|
Description: Rabbit polyclonal PKC nu antibody |
|||
 EZSolution? NU-7441 |
|||
| B1875-5 | Biovision | EUR 185 | |
 EpiQuik Global Histone H3 Acetylation Assay Kit |
|||
| P-4008 | EpiGentek | 96 Assays | EUR 788.05 |
|
Description: kits suitable for this type of research |
|||
 Human TDP2 Assay Kit |
|||
| TG1005-1 | TopoGen | 100 assays | EUR 537 |
 Polyclonal PKC nu Antibody |
|||
| APR14376G | Leading Biology | 0.1ml | EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PKC nu . This antibody is tested and proven to work in the following applications: |
|||
) Anti-PKC nu (4G7) |
|||
| YF-MA17975 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to PKC nu |
|||
 EZSolution? Q-VD-OPh, Negative Control |
|||
| 1174-1 | Biovision | EUR 207 | |
 Caspase-3 Inhibitor Q-DEVD-OPh |
|||
| 1175-1 | Biovision | EUR 272 | |
 Caspase-8 Inhibitor, Q-IETD-OPh |
|||
| 1176-1 | Biovision | EUR 305 | |
 Caspase-9 Inhibitor, Q-LEHD-OPh |
|||
| 1177-1 | Biovision | EUR 294 | |